Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease

Hua Long,Adam Simmons,Arthur Mayorga,Brady Burgess,Tuan Nguyen,Balasubrahmanyam Budda,Anna Rychkova,Herve Rhinn,Ilaria Tassi,Michael Ward,Felix Yeh,Tina Schwabe,Robert Paul,Sara Kenkare-Mitra,Arnon Rosenthal

DOI: https://doi.org/10.1186/s13195-024-01599-1

2024-10-24

Alzheimer s Research & Therapy

Abstract:Variants of the gene triggering receptor expressed on myeloid cells-2 (TREM2) increase the risk of Alzheimer's disease (AD) and other neurodegenerative disorders. Signaling by TREM2, an innate immune receptor expressed by microglia, is thought to enhance phagocytosis of amyloid beta (Aβ) and other damaged proteins, promote microglial proliferation, migration, and survival, and regulate inflammatory signaling. Thus, TREM2 activation has potential to alter the progression of AD. AL002 is an investigational, engineered, humanized monoclonal immunoglobulin G1 (IgG1) antibody designed to target TREM2. In AD mouse models, an AL002 murine variant has been previously shown to induce microglial proliferation and reduce filamentous Aβ plaques and neurite dystrophy.

neurosciences,clinical neurology